Drugs / Pvs25-IMX313
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05270265 | Feb 2022 → Jul 2023 | Plasmodium vivax malaria | University of Oxford | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pvs25-IMX313 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05270265 ↗ |
| Modality | Vaccine | “Pvs25-IMX313 vaccine” NCT05270265 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT05270265 ↗ |